Favorite this paper
How to cite this paper?
Abstract

CASE PRESENTATION
            A 37-years-old female patient with highly active relapsing-remitting multiple sclerosis (RRMS) was admitted for Alemtuzumab treatment. The formal protocol of 12mg for five days with 1g of methylprednisolone daily for the first three days plus concomitantly acyclovir, diphenhydramine and acetaminophen (< 4g daily) was performed.
            Upon the third day of infusion an unexpected rising of her liver function tests was detected. Basal ALT raised from 20 U/L to 1441 U/L on day three, with an AST of 522 U/L, ALP of 119 U/L, GGT of 433 U/L and bilirubin of 0,5 mg/dL. There were no signs of acute liver failure such as encephalopathy, coagulopathy, hepatomegaly or hepatorenal syndrome. Serologies were negative (hepatitis A, B and C antibodies, cytomegalovirus and Ebstein-Barr virus IgM). Antinuclear, antimitochondrial, anti-LKM1 and anti-smooth muscle antibodies were negative.
           The Gastroenterology team was consulted and a drug induced liver injury (DILI) associated with Alemtuzumab was suspected. The Roussel Uclaf Causality Assessment Method (RUCAM) score was six, making DILI “probable”. Alemtuzumab was definitely interrupted at the fourth day of treatment, coinciding with a drop in ALT from 440 U/L on day eight. Nowadays patient is in regular treatment with Rituximab.

DISCUSSION
         Alemtuzumab is a monoclonal antibody to human CD52 on lymphocytes. It is a highly effective therapy for RRMS treatment. Alemtuzumab is related with some adverse events, including opportunistic infections and autoimmunity. Thyroid disorders, immune thrombocytopenic purpura, nephropathies, and autoimmune hepatitis has been described. Despite previously related autoimmune hepatitis, DILI is an unexpected adverse effect for this medication.

FINAL COMMENTS
  
       We report a case of an acute non-autoimmune hepatitis induced by Alemtuzumab in a patient with RRMS during the first round of treatment. To our knowledge this is the second published report of DILI associated with Alemtuzumab, therefore highlighting the scientific relevance of this case report.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo
  • 2 Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, Brazil
Track
  • 4. MS treatment
Keywords
Multiple sclerosis
Alemtuzumab
Hepatotoxicity